In glioblastomas, the CD47 pathway has been shown to significantly enhance M1-mediated phagocytosis of glioma cells, resulting in slowed tumor growth and prolonged survival times, with minimal to no side effects observed in both in vitro and in vivo models [29,32,34,39]. This evidence concerns the gene CD47 and glioblastoma.